Login to Your Account



FDA rejects Sunovion new drug app for COPD drug and nebulizer

By Michael Fitzhugh
Staff Writer

Tuesday, May 30, 2017

An FDA CRL for the COPD therapy SUN-101 and the Eflow nebulizer used to deliver it is sending Sunovion Pharmaceuticals Inc. back into talks with the agency and pushing out the potential realization of up to $210 million in commercial milestones for former backers of Elevation Pharmaceuticals Inc., from which Sunovion acquired the program in 2012.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription